NCT04537429View on ClinicalTrials.gov

A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 4, 2020

Primary Completion Date

October 20, 2022

Study Completion Date

August 21, 2023

Conditions
Migraine in ChildrenMigraine
Interventions
DRUG

Eptinezumab

up to four iv infusions of eptinezumab

Trial Locations (9)

32561

NW FL Clinical Research Group LLC, Gulf Breeze

48104

Michigan Head Pain and Neurological Institute, Ann Arbor

66212

College Park Family Care Center, Overland Park

75034

North Texas Institute of Neurology & Headache, Frisco

78249

Road Runner Research Ltd, San Antonio

84107

Wasatch Clinical Research, Salt Lake City

06905

New England Institute for Clinical Research, Stamford

33407-3234

The Premiere Research Institute at Palm Beach Neurology, West Palm Beach

15236-4604

Preferred Primary Care Physicians Inc., Pittsburgh

All Listed Sponsors
lead

H. Lundbeck A/S

INDUSTRY

NCT04537429 - A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab | Biotech Hunter | Biotech Hunter